AQUATIC Study: Aspirin & Anticoagulation in Chronic CAD
The AQUATIC study, featured in NEJM, represents a pivotal investigation into the complex balance of antithrombotic therapy for patients with chronic coronary syndrome (CCS) who are already on oral anticoagulation. This double-blind, placebo-controlled, randomized trial is groundbreaking as it specifically targets a high-risk population: individuals with a history of coronary stenting and elevated atherothrombotic risk. Previous studies in this domain have explored similar therapies, but AQUATIC uniquely focuses on this particularly vulnerable patient group, where the risk of cardiovascular events was notably 7 to 8 times higher than in earlier trials.
The primary objective of AQUATIC is to meticulously evaluate the risks and benefits of adding low-dose aspirin to existing oral anticoagulation therapy. The potential benefits center on reducing the incidence of ischemic events, such as myocardial infarction, stroke, or other thrombotic complications, which are a significant concern in patients with advanced coronary artery disease and high atherothrombotic burden. For instance, preventing stent thrombosis or further atherosclerotic events could significantly improve patient outcomes and quality of life.
However, the introduction of aspirin alongside an oral anticoagulant carries a well-documented risk of increased bleeding. This includes potential for major bleeding events, such as gastrointestinal hemorrhage or intracranial bleeding, which can be life-threatening. The study’s rigorous design aims to precisely quantify this bleeding risk against any observed reduction in ischemic events, thereby providing crucial evidence to guide clinical decision-making. The findings are expected to inform whether the enhanced protection against ischemic events outweighs the heightened risk of bleeding in this specific, high-risk cohort, ultimately shaping future treatment guidelines for managing these challenging patients.
